Tomuleasa C - Search Results

1

Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis.

Teodorescu P, Pasca S, Jurj A, Gafencu G, Joelsson JP, Selicean S, Moldovan C, Munteanu R, Onaciu A, Tigu AB, Buse M, Zimta AA, Stiufiuc R, Petrushev B, Desmirean M, Dima D, Vlad C, Bergthorsson JT, Berce C, Ciurea S, Ghiaur G, Tomuleasa C. Teodorescu P, et al. Among authors: tomuleasa c. J Cell Mol Med. 2020 Oct;24(19):11100-11110. doi: 10.1111/jcmm.15526. Epub 2020 Sep 5. J Cell Mol Med. 2020. PMID: 32889753 Free PMC article.

2

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.

Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A, Kacso G. Tomuleasa C, et al. Hematol Oncol Stem Cell Ther. 2011;4(2):60-6. doi: 10.5144/1658-3876.2011.60. Hematol Oncol Stem Cell Ther. 2011. PMID: 21727766 Free article.

3

Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology?

Aldea M, Tomuleasa C, Petrushev B, Susman S, Kacso GI, Irimie A, Florian IS, Soritau O. Aldea M, et al. Among authors: tomuleasa c. J BUON. 2011 Jul-Sep;16(3):409-13. J BUON. 2011. PMID: 22006741 Review.

4

Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.

Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, Kacso G, Berindan I, Irimie A, Cristea V. Petrushev B, et al. Among authors: tomuleasa c. Exp Oncol. 2012;34(1):17-24. Exp Oncol. 2012. PMID: 22453143

5

The axis of evil in the fight against cancer.

Petrushev B, Tomuleasa C, Suşman S, Sorişău O, Aldea M, Kacsó G, Buigă R, Irimie A. Petrushev B, et al. Among authors: tomuleasa c. Rom J Intern Med. 2011;49(4):319-25. Rom J Intern Med. 2011. PMID: 22568277 Review.

6

Paraneoplastic syndromes with connective tissue involvement. "It's not always lupus!".

Timis T, Berce C, Duarte-Garcia A, Petrushev B, Cristea V, Tomuleasa C. Timis T, et al. Among authors: tomuleasa c. J BUON. 2012 Jul-Sep;17(3):417-21. J BUON. 2012. PMID: 23033275 Review.

7

MRI-based identification of undifferentiated cells: looking at the two faces of Janus.

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. Tomuleasa C, et al. Int J Nanomedicine. 2014 Feb 11;9:865-6. doi: 10.2147/IJN.S58674. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24596462 Free PMC article. No abstract available.

8

Cancer stem-like cells: the dark knights of clinical hematology and oncology.

Frinc I, Muresan MS, Zaharie F, Petrov L, Irimie A, Berce C, Berindan-Neagoe I, Tomuleasa C. Frinc I, et al. Among authors: tomuleasa c. J BUON. 2014 Apr-Jun;19(2):328-35. J BUON. 2014. PMID: 24965388 Free article. Review.

9

Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells.

Aldea MD, Petrushev B, Soritau O, Tomuleasa CI, Berindan-Neagoe I, Filip AG, Chereches G, Cenariu M, Craciun L, Tatomir C, Florian IS, Crivii CB, Kacso G. Aldea MD, et al. Among authors: tomuleasa ci. J BUON. 2014 Apr-Jun;19(2):502-11. J BUON. 2014. PMID: 24965413 Free article.

10

BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice.

Tomuleasa C, Dima D, Frinc I, Patiu M, Petrushev B, Cucuianu A, Berindan-Neagoe I. Tomuleasa C, et al. Leuk Lymphoma. 2015 Feb;56(2):546-7. doi: 10.3109/10428194.2014.940582. Epub 2014 Aug 19. Leuk Lymphoma. 2015. PMID: 25012945 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters